218 related articles for article (PubMed ID: 26211823)
1. Postmenopausal breast cancer: a best endocrine strategy?
Mayer EL; Burstein HJ
Lancet; 2015 Oct; 386(10001):1317-1319. PubMed ID: 26211823
[No Abstract] [Full Text] [Related]
2. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors for breast cancer.
Briest S; Davidson NE
Rev Endocr Metab Disord; 2007 Sep; 8(3):215-28. PubMed ID: 17486453
[TBL] [Abstract][Full Text] [Related]
4. Effect of a switch of aromatase inhibitors to another aromatase inhibitor or tamoxifen on musculoskeletal symptoms in breast cancer; Which is the best?
Altundag K
J BUON; 2020; 25(4):2132. PubMed ID: 33099971
[No Abstract] [Full Text] [Related]
5. Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
Morales L; Paridaens R; Timmerman D; Neven P
Clin Cancer Res; 2006 Sep; 12(18):5603. PubMed ID: 17000698
[No Abstract] [Full Text] [Related]
6. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Cunnick G; Mokbel K
Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
8. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
9. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
11. By the way, doctor. Should I switch from tamoxifen to an aromatase inhibitor?
Robb-Nicholson C
Harv Womens Health Watch; 2007 Jun; 14(10):8. PubMed ID: 18018318
[No Abstract] [Full Text] [Related]
12. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
13. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
14. Aromatase inhibitors: what is the true cost?
Houston KE; Thomson DB
Intern Med J; 2011 Feb; 41(2):139-40. PubMed ID: 22747552
[No Abstract] [Full Text] [Related]
15. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
Petrelli F; Barni S
Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
[No Abstract] [Full Text] [Related]
16. Adherence with adjuvant hormonal therapy for breast cancer.
Ruddy KJ; Partridge AH
Ann Oncol; 2009 Mar; 20(3):401-2. PubMed ID: 19246419
[No Abstract] [Full Text] [Related]
17. Exemestane or tamoxifen?
Atkins CD
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
[No Abstract] [Full Text] [Related]
18. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
19. Switching to aromatase inhibitors in early breast cancer.
Boccardo F; Rubagotti A
Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
[No Abstract] [Full Text] [Related]
20. The role of aromatase inhibitor (AI) in the treatment of breast cancer.
Irawan C; Abdulmuthalib
Acta Med Indones; 2005; 37(1):43-8. PubMed ID: 15879638
[No Abstract] [Full Text] [Related]
[Next] [New Search]
